TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18509121
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg prucalopride
Study: 18509121
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg and 4 mg prucalopride
Study: 24068395
Drug: Radiochemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiochemotherapy with molecular anti-EGFR target therapy
Study: 19912736
Drug: Shenyi Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenyi Capsule combined with gemcitabine plus cisplatin (GP) regimen
Study: 15247911
Drug: 9-valent pneumococcal
Normalized name: L1 protein, human papillomavirus type 31 vaccine
DrugBank: Human papillomavirus type 31 L1 capsid protein antigen (DB10310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9-valent pneumococcal conjugate vaccine (PncCV)
Study: 30488789
Drug: Dalteparin (low-molecular-weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin (low-molecular-weight heparin)
Study: 9296467
Drug: Dalteparin (lower
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin (lower dose)
Study: 9296467
Drug: Dalteparin (twice-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin (twice-daily administration)
Study: 8395472
Drug: 20% CHO
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% CHO (L‐CHO) and 60% fat (group 3; 7 subjects)
Study: 3530305
Drug: Oral lamotrigine
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral lamotrigine (240 mg)
Study: 28726590
Drug: Low-/moderate-dose hypertonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-/moderate-dose hypertonic saline
Study: 24486426
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (C) (n=76)
Study: 19728091
Drug: Internet-based gender-specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based gender-specific drug prevention program (12 sessions)
Study: 10492858
Drug: Twice weekly
Normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice weekly ECT
Study: 9821454
Drug: Three times
Normalized name: WELLBUTRIN 100 MG Oral Tablet, Three Times Daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three times weekly ECT
Study: 8698227
Drug: Gastric permeability
Normalized name: gastric mucins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastric permeability measured by oral or duodenal administration of a triple sugar solution (20 g sucrose, 10 g lactulose, 5 g mannitol in 100 mL water)
Study: 1894758
Drug: 150‐mg phenylpropanolamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150‐mg phenylpropanolamine
Study: 1894758
Drug: 75‐mg phenylpropanolamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75‐mg phenylpropanolamine
Study: 1894758
Drug: 75‐mg phenylpropanolamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75‐mg phenylpropanolamine plus 400‐mg caffeine
Study: 6225150
Drug: Zimelidine (75-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zimelidine (75-300 mg/day)
Study: 6225150
Drug: Amitriptyline (dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (dosage not specified)
Study: 27841155
Drug: Vilaprisan 5
Normalized name: Vilaprisan
DrugBank: Vilaprisan (DB11971)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vilaprisan 5 mg
Study: 27841155
Drug: Vilaprisan 15
Normalized name: Vilaprisan
DrugBank: Vilaprisan (DB11971)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vilaprisan 15 mg
Study: 25186261
Drug: fluticasone propionate/salmeterol
Normalized name: fluticasone propionate/salmeterol 100/50 MCG/INHAL Dry Powder Inhaler, 14 Blisters
Approvals — FDA: no, EMA: no, PMDA: no
Description: fluticasone propionate/salmeterol combination
Study: 8943962
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg daily
Study: 9698952
Drug: Bupivacaine 0.12%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.12% with fentanyl 2 micrograms/ml
Study: 9698952
Drug: Bupivacaine 0.24%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.24% with fentanyl 4 micrograms/ml
Study: 28661759
Drug: Epirubicin (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin (90 mg/m2) and cyclophosphamide (600 mg/m2) followed by docetaxel (100 mg/m2; EC-D)
Study: 28661759
Drug: Docetaxel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (75 mg/m2) and cyclophosphamide (600 mg/m2; DC)
Study: 25937436
Drug: Sofosbuvir 400
Normalized name: sofosbuvir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir 400 mg and ribavirin 1000-1200 mg daily for 24 weeks
Study: 25937436
Drug: Sofosbuvir 400
Normalized name: sofosbuvir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir 400 mg and ribavirin 1000-1200 mg daily for 12 weeks
Study: 25937436
Drug: Sofosbuvir 400
Normalized name: sofosbuvir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir 400 mg and ribavirin for 24 weeks in patients with cirrhosis
Study: 16775230
Drug: subcutaneous interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous interferon beta‐1a at 22 mug, three times weekly
Study: 12959273
Drug: Nifedipine GITS
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine GITS (60 mg)
Study: 18306163
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Er:YAG laser ablation and ALA methyl ester PDT (method C)
Study: 18306163
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) only (method A)
Study: 11994041
Drug: Fluconazole 150
Normalized name: fluconazole 150 MG
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole 150 mg once weekly for 12 weeks
Study: 11994041
Drug: Fluconazole 150
Normalized name: fluconazole 150 MG
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole 150 mg once weekly for 24 weeks
Study: 2121846
Drug: Praziquantel (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel (40 mg/kg orally every 6 months)
Study: 2121846
Drug: Praziquantel (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel (initial full dose of 40 mg/kg followed by 20 mg/kg every 3 months)
Study: 2121846
Drug: Praziquantel (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel (initial loading dose followed by 20 mg/kg at monthly intervals)
Study: 2121846
Drug: Praziquantel (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel (20 mg/kg orally every 3 months)
Study: 2121846
Drug: Placebo (vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (vitamin B complex tablets at 3-month intervals)
Study: 2121846
Drug: Praziquantel (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel (20 mg/kg orally monthly for urinary hematobiasis)
Study: 2121846
Drug: Placebo (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (two vitamin B-complex tablets monthly for urinary hematobiasis)
Study: 31190359
Drug: Flaxseed oil
Normalized name: Flaxseed Oil
DrugBank: Linseed oil (DB11357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed oil (1,000 mg omega-3 fatty acids, twice a day for 12 weeks)
Study: 24304731
Drug: Metformin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1 g/day) for 12 weeks
Study: 21729238
Drug: Levothyroxine 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levothyroxine 0.3 mg per day
Study: 16409456
Drug: 9000 aXa-units
Normalized name: Axatilimab
DrugBank: Axatilimab (DB16388)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9000 aXa-units of unfractionated heparin (UFH)
Study: 15354517
Drug: Antibiotic prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prophylaxis (Group B)
Study: 15354517
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (Group D)
Study: 10954344
Drug: Oral cocaine
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cocaine administration
Study: 1729427
Drug: Intravenous cocaine
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cocaine administration
Study: 8859258
Drug: Furosemide (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (2 mg/kg) in patients with HPS
Study: 8859258
Drug: Furosemide therapy
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide therapy in patients with HPS
Study: 8859258
Drug: Furosemide therapy
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide therapy in healthy children
Study: 9387348
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (Group A)
Study: 17400981
Drug: Fast injection
Normalized name: Fast Freeze
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fast injection (over four seconds, Group F) of 0.75% hyperbaric bupivacaine 12 mg plus morphine 200 microg
Study: 17400981
Drug: Slow injection
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow injection (over 40 seconds, Group S) of 0.75% hyperbaric bupivacaine 12 mg plus morphine 200 microg
Study: 12175715
Drug: Isosorbide mononitrate
Normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide mononitrate (IMN) 40 mg vaginally
Study: 25163444
Drug: 3‐mg melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3‐mg melatonin
Study: 25163444
Drug: 5‐mg melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐mg melatonin
Study: 15894688
Drug: Diet with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet with 63 g of sugars for 10 days
Study: 15894688
Drug: Diet with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet with 143 g of sugars for 10 days
Study: 15894688
Drug: Diet with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet with 264 g of sugars for 10 days
Study: 7095978
Drug: Intranasal cocaine
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal cocaine hydrochloride (0.75 mg/kg)
Study: 7095978
Drug: Intranasal cocaine
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal cocaine hydrochloride (1.5 mg/kg)
Study: 7095978
Drug: Intranasal lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal lidocaine hydrochloride (0.2 mg/kg)
Study: 31399906
Drug: Apatinib 250
Normalized name: lapatinib 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib 250 mg/day during chemotherapy interval and as maintenance therapy
Study: 31614909
Drug: Eyewash solution
DrugBank: Boric acid (DB11326)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eyewash solution (preservative-free)
Study: 23660289
Drug: Intra-arterial tirofiban
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial tirofiban infusion
Study: 30669797
Drug: Parecoxib (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parecoxib (40 mg)
Study: 21354925
Drug: PCA with
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA with morphine doses at 0 mg (P(1))
Study: 21354925
Drug: PCA with
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA with morphine doses at 5 mg (P(2))
Study: 21354925
Drug: PCA with
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA with morphine doses at 10 mg (P(3))
Study: 21354925
Drug: PCA with
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA with morphine doses at 15 mg (P(4))
Study: 21354925
Drug: PCA with
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA with morphine doses at 20 mg (P(5))
Study: 17556628
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of azithromycin, ivermectin, and albendazole
Study: 17556628
Drug: Ivermectin and
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin and albendazole combination
Study: 15167732
Drug: Preincisional retrobulbar
Normalized name: bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preincisional retrobulbar injection containing bupivacaine, lidocaine, epinephrine, and hyaluronidase
Study: 11677191
Drug: Cholestyramine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholestyramine treatment for 2 weeks
Study: 11677191
Drug: Cholestyramine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholestyramine treatment in patients with elevated cholesterol levels
Study: 7786693
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulphate therapy (1.0 g bolus followed by 1.0 g every hour for three hours, then 1.0 g every 6 hours for 24 hours)
Study: 7786693
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no magnesium sulphate therapy)
Study: 3057900
Drug: Anti-cholera toxin
Normalized name: VIBRIO CHOLERAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-cholera toxin bovine colostral immunoglobulins (2 g in 100 ml of water, two doses in Trial I; 2 g every two hours for a total of eight doses in Trial II)
Study: 3057900
Drug: Non-immune bovine
Normalized name: Pegademase Bovine
DrugBank: Pegademase (DB00061)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-immune bovine colostral immunoglobulins (two doses in Trial I; 2 g every two hours for a total of eight doses in Trial II)
Study: 3057900
Drug: Water (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water (100 ml alone in Trial I; 100 ml every two hours for a total of eight doses in Trial II)
Study: 19959168
Drug: Miglustat therapy
Normalized name: Miglustat
DrugBank: Miglustat (DB00419)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Miglustat therapy
Study: 10534727
Drug: Recombinant hepatitis
Normalized name: Recombinant hepatitis B human immunoglobulin
DrugBank: Lenvervimab (DB17814)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant hepatitis B vaccine (20 microg/dose) given in months 0, 1, and 6 to group II (35 healthy subjects)
Study: 7785755
Drug: Isoflurane anesthesia
Normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoflurane anesthesia (methohexital 1-2 mg/kg for induction, isoflurane 0.4-2.0 vol% for maintenance)
Study: 9734576
Drug: Adjuvant psychological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant psychological group therapy
Study: 8291822
Drug: Doxycycline, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline, 100 mg, once daily
Study: 3397588
Drug: iso-osmolar test
Normalized name: iso-sulfan blue
Approvals — FDA: no, EMA: no, PMDA: no
Description: iso-osmolar test solutions
Study: 3397588
Drug: hyperosmolar test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: hyperosmolar test solutions
Study: 3397588
Drug: D-xylose absorption
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-xylose absorption
Study: 3397588
Drug: lactulose and
Normalized name: Lactulose
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: lactulose and L-rhamnose permeation
Study: 21507036
Drug: Topical PUVAsol
Normalized name: docusate sodium / sennosides, USP Oral Tablet [Purgasol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical PUVAsol on alternate days for 16 weeks
Study: 21727006
Drug: Ibandronate 6
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate 6 mg infused over 15 min
Study: 16703289
Drug: Xerostomia group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xerostomia group (salivary flow < 0.2 ml/min)
Study: 16703289
Drug: Nonxerostomia group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonxerostomia group (salivary flow > 0.2 ml/min)
Study: 10718161
Drug: Weekly relapse
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly relapse prevention therapy
Study: 3498281
Drug: Combination heat
Normalized name: norethindrone
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combination heat supply group (12 patients)
Study: 18472087
Drug: Demineralisation solution
Normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Demineralisation solution with 1 ppm fluoride for five days
Study: 9621483
Drug: EPI (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPI (160 mg/m2 i.v. every 3 weeks)
Study: 3279968
Drug: Acipimox 750
Normalized name: acipimox
DrugBank: Acipimox (DB09055)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox 750 mg/day for first 6 months, then 1200 mg/day for last 3 months
Study: 30673687
Drug: Individualized exercise
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized exercise prescription
Study: 30673687
Drug: Standardized exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized exercise prescription
Study: 21178179
Drug: Ewes fed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ewes fed ASe (3.05 μg/kg of BW)
Study: 21178179
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Se treatment and late gestation nutritional level
Study: 19500346
Drug: Stepped care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepped care program consisting of Watchful waiting, Guided self-help, Problem Solving Treatment, Medication and/or specialized mental health care
Study: 14765861
Drug: Oral ferrous
Normalized name: ferrous fumarate Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ferrous sulphate for six weeks
Study: 11739066
Drug: Carbamazepine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine (400 mg/day)
Study: 3284549
Drug: Defibrinogenation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Defibrinogenation therapy
Study: 22050040
Drug: Brimonidine tartrate
Normalized name: Brimonidine Tartrate
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brimonidine tartrate (BT) 0.5% once daily
Study: 22050040
Drug: Brimonidine tartrate
Normalized name: Brimonidine Tartrate
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brimonidine tartrate (BT) 0.18% once daily
Study: 28095573
Drug: Vehicle once
Normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vehicle once daily
Study: 22050040
Drug: Brimonidine tartrate
Normalized name: Brimonidine Tartrate
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brimonidine tartrate (BT) 0.18% twice daily
Study: 18279480
Drug: Antibacterial agents
Normalized name: Dermoplast Antibacterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibacterial agents RCTs
Study: 10220833
Drug: No medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: No medication or nonsteroidal antirheumatic drugs
Study: 8935108
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of enamel etching and dentinal bonding (n = 188)
Study: 12675
Drug: Injectable combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable combination of local anaesthetic (Xylestesin) and beta-receptor-blocker (Betadrenol)
Study: 27732968
Drug: Paclitaxel (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (standard dose and schedule)
Study: 23948958
Drug: High-dose statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose statin therapy
Study: 12519653
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg arecoline
Study: 12519653
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg arecoline
Study: 12519653
Drug: Areca nut
Normalized name: Areca catechu seed extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Areca nut (various doses)
Study: 9086386
Drug: Sequential compression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential compression device (SCD + TED)
Study: 8460756
Drug: Omeprazole 80
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole 80 mg + Metoclopramide 10 mg (group 4)
Study: 8460756
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg (group 1)
Study: 8460756
Drug: Omeprazole 80
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole 80 mg (group 2)
Study: 8460756
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg + Metoclopramide 10 mg (group 3)
Study: 3956895
Drug: 20 min
Normalized name: wheat germ oil 20 minim ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 min daily bicycle exercise
Study: 23194486
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous diuretics
Study: 23194486
Drug: Bolus intravenous
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus intravenous diuretics
Study: 23194486
Drug: High initial
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High initial intravenous diuretic dose
Study: 23194486
Drug: Low initial
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low initial intravenous diuretic dose
Study: 23194486
Drug: High outpatient
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High outpatient diuretic doses
Study: 23194486
Drug: Low outpatient
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low outpatient diuretic doses
Study: 23194486
Drug: Mode of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mode of therapy (bolus vs continuous)
Study: 11171733
Drug: Filgrastim (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filgrastim (300 microg) administered IV daily for up to 5 days